Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that the European Commission (EC) has revoked the marketing authorization for Aumolertinib, just seven months after its EU approval in February 2026. The revocation follows a lawsuit filed by AstraZeneca (NYSE: AZN) against the EC in the General Court of the European Union (Case T‑289/26) and centers on the citation of still‑protected clinical data from AstraZeneca’s originator drug TAGRISSO in Hansoh’s application dossier — a procedural defect in the regulatory evaluation process.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | European Commission (EC), European Union |
| Action | Revocation of marketing authorization |
| Product | Aumolertinib (third‑generation EGFR tyrosine kinase inhibitor) |
| Original Approval | 12 Feb 2026 |
| Revocation Announced | 27 Sep 2026 |
| Legal Trigger | AstraZeneca v. European Commission, Case T‑289/26, General Court of the EU (filed 7 May 2026, seeking annulment of the 12 Feb approval decision) |
| Primary Basis | Dossier cited certain TAGRISSO clinical results as background reference while those data were still under EU data protection — a procedural issue in regulatory evaluation |
| Procedural Note | EC initiated the revocation process before the court rendered judgment |
| Next Steps | Not disclosed (status of Case T‑289/26; any resubmission plans) |
Dispute Timeline
| Date | Event |
|---|---|
| 4 Feb 2016 | TAGRISSO’s EU marketing authorization takes effect |
| Feb 2016 – Feb 2024 | TAGRISSO’s EU data protection period |
| 1 Dec 2022 | Hansoh submits Aumolertinib’s marketing authorization application to the EC — within the protection window |
| 12 Feb 2026 | EC approves Aumolertinib for marketing in the EU |
| 7 May 2026 | AstraZeneca files Case T‑289/26 seeking annulment of the approval decision |
| Pre‑judgment | EC initiates revocation of Aumolertinib’s marketing authorization |
| 27 Sep 2026 | Hansoh announces the revocation |
Drug Profile & Dossier Background
- Molecule: Aumolertinib — an oral third‑generation EGFR tyrosine kinase inhibitor (TKI) and Hansoh’s flagship oncology asset, marketed in China since 2020.
- Drug Class Context: Third‑generation EGFR TKIs target activating EGFR mutations and the T790M resistance mutation in non‑small cell lung cancer (NSCLC); Aumolertinib competes directly in the class pioneered by AstraZeneca’s originator product TAGRISSO (osimertinib).
- Dossier Basis: Hansoh’s EU application included complete, independently generated Phase III clinical data and European pharmacokinetic (PK) bridging data.
- Nature of the Defect: The revocation’s primary basis was procedural — certain TAGRISSO clinical results cited in the dossier as background reference were still under data protection at the time of submission, not a challenge to Aumolertinib’s own clinical data.
- EU Data‑Protection Framework: EU law grants originator biologics and small molecules a defined data‑protection window (eight years from authorization for TAGRISSO: Feb 2016 → Feb 2024). An application submitted on 1 Dec 2022 that relies on, or references as background, protected originator data falls inside that window — rendering the regulatory evaluation procedurally vulnerable even after approval is granted.
Market Impact & Outlook
- AstraZeneca Outcome: By prompting revocation before the General Court ruled, AstraZeneca effectively removed a competing third‑generation EGFR TKI from the EU market and reinforced TAGRISSO’s commercial position in Europe.
- Hansoh Globalization Setback: EU approval had marked a milestone in Hansoh’s international expansion; losing it seven months after grant disrupts the company’s European commercialization trajectory. The status of Aumolertinib filings in other ex‑China regions was not disclosed.
- China Franchise Unaffected: The revocation applies solely to the EU marketing authorization; Aumolertinib’s approval and commercialization in China are untouched by the EC’s decision.
- Compliance Precedent: The case underscores the rigidity of EU data‑exclusivity enforcement — even background citations of protected originator data can invalidate an authorization years after submission, a cautionary precedent for Chinese pharma firms building global dossiers.
- Potential Path Forward: Because TAGRISSO’s data protection expired in February 2024, a freshly prepared resubmission would not face the same timing defect; whether Hansoh intends to refile, and the disposition of Case T‑289/26 following the revocation, were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory proceedings, potential resubmissions, and commercial expectations for Aumolertinib. Actual outcomes may differ materially due to risks including pending litigation before the General Court of the European Union, regulatory decisions on any future application, and competitive dynamics in the third‑generation EGFR TKI market.-Fineline Info & Tech
